A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer

Harold Harvey, Richard J. Santen, Juraj Osterman, Eugeniusz Samojlik, Deborah S. White, Allan Lipton

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We compared two treatment regimens, transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in women with metastatic breast carcinoma. Three of fourteen patients experienced partial objective tumor regression with a median duration of 4.6 months following hypophysectomy, whereas 10 of 21 women receiving aminoglutethimide responded (2 complete, 8 partial) with a median duration of 11.5 months. Side effects in the medical group were minimal while surgical complications included 2 cases of CSF rhinorrhea, one leading to meningitis and death. In patients receiving aminoglutethimide, urinary free cortisol and plasma dehydroepiandrosterone sulfate fell significantly as did plasma estrone and estradiol. In the hypophysectomy group, anterior‐pituitary function testing postoperatively revealed adequate suppression of gonadotropin and prolactin secretion but incomplete inhibition of the ACTH‐cortisol axis in 4 of 7 surgical patients studied. Five patients initially treated with hypophysectomy experienced a further reduction of plasma (and urinary) estrone and estradiol levels when given aminoglutethimide. We conclude that estrogen suppression therapy with aminoglutethimide is a feasible alternative to surgical hypophysectomy in providing endocrine suppression and palliation in advanced breast carcinoma.

Original languageEnglish (US)
Pages (from-to)2207-2214
Number of pages8
JournalCancer
Volume43
Issue number6
DOIs
StatePublished - Jan 1 1979

Fingerprint

Aminoglutethimide
Hypophysectomy
Estrogens
Breast Neoplasms
Estrone
Estradiol
Cerebrospinal Fluid Rhinorrhea
Dehydroepiandrosterone Sulfate
Gonadotropins
Meningitis
Prolactin
Hydrocortisone
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Harvey, Harold ; Santen, Richard J. ; Osterman, Juraj ; Samojlik, Eugeniusz ; White, Deborah S. ; Lipton, Allan. / A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. In: Cancer. 1979 ; Vol. 43, No. 6. pp. 2207-2214.
@article{54c4dc82218d41e6bb839083c6535f5a,
title = "A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer",
abstract = "We compared two treatment regimens, transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in women with metastatic breast carcinoma. Three of fourteen patients experienced partial objective tumor regression with a median duration of 4.6 months following hypophysectomy, whereas 10 of 21 women receiving aminoglutethimide responded (2 complete, 8 partial) with a median duration of 11.5 months. Side effects in the medical group were minimal while surgical complications included 2 cases of CSF rhinorrhea, one leading to meningitis and death. In patients receiving aminoglutethimide, urinary free cortisol and plasma dehydroepiandrosterone sulfate fell significantly as did plasma estrone and estradiol. In the hypophysectomy group, anterior‐pituitary function testing postoperatively revealed adequate suppression of gonadotropin and prolactin secretion but incomplete inhibition of the ACTH‐cortisol axis in 4 of 7 surgical patients studied. Five patients initially treated with hypophysectomy experienced a further reduction of plasma (and urinary) estrone and estradiol levels when given aminoglutethimide. We conclude that estrogen suppression therapy with aminoglutethimide is a feasible alternative to surgical hypophysectomy in providing endocrine suppression and palliation in advanced breast carcinoma.",
author = "Harold Harvey and Santen, {Richard J.} and Juraj Osterman and Eugeniusz Samojlik and White, {Deborah S.} and Allan Lipton",
year = "1979",
month = "1",
day = "1",
doi = "10.1002/1097-0142(197906)43:6<2207::AID-CNCR2820430608>3.0.CO;2-1",
language = "English (US)",
volume = "43",
pages = "2207--2214",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. / Harvey, Harold; Santen, Richard J.; Osterman, Juraj; Samojlik, Eugeniusz; White, Deborah S.; Lipton, Allan.

In: Cancer, Vol. 43, No. 6, 01.01.1979, p. 2207-2214.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer

AU - Harvey, Harold

AU - Santen, Richard J.

AU - Osterman, Juraj

AU - Samojlik, Eugeniusz

AU - White, Deborah S.

AU - Lipton, Allan

PY - 1979/1/1

Y1 - 1979/1/1

N2 - We compared two treatment regimens, transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in women with metastatic breast carcinoma. Three of fourteen patients experienced partial objective tumor regression with a median duration of 4.6 months following hypophysectomy, whereas 10 of 21 women receiving aminoglutethimide responded (2 complete, 8 partial) with a median duration of 11.5 months. Side effects in the medical group were minimal while surgical complications included 2 cases of CSF rhinorrhea, one leading to meningitis and death. In patients receiving aminoglutethimide, urinary free cortisol and plasma dehydroepiandrosterone sulfate fell significantly as did plasma estrone and estradiol. In the hypophysectomy group, anterior‐pituitary function testing postoperatively revealed adequate suppression of gonadotropin and prolactin secretion but incomplete inhibition of the ACTH‐cortisol axis in 4 of 7 surgical patients studied. Five patients initially treated with hypophysectomy experienced a further reduction of plasma (and urinary) estrone and estradiol levels when given aminoglutethimide. We conclude that estrogen suppression therapy with aminoglutethimide is a feasible alternative to surgical hypophysectomy in providing endocrine suppression and palliation in advanced breast carcinoma.

AB - We compared two treatment regimens, transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in women with metastatic breast carcinoma. Three of fourteen patients experienced partial objective tumor regression with a median duration of 4.6 months following hypophysectomy, whereas 10 of 21 women receiving aminoglutethimide responded (2 complete, 8 partial) with a median duration of 11.5 months. Side effects in the medical group were minimal while surgical complications included 2 cases of CSF rhinorrhea, one leading to meningitis and death. In patients receiving aminoglutethimide, urinary free cortisol and plasma dehydroepiandrosterone sulfate fell significantly as did plasma estrone and estradiol. In the hypophysectomy group, anterior‐pituitary function testing postoperatively revealed adequate suppression of gonadotropin and prolactin secretion but incomplete inhibition of the ACTH‐cortisol axis in 4 of 7 surgical patients studied. Five patients initially treated with hypophysectomy experienced a further reduction of plasma (and urinary) estrone and estradiol levels when given aminoglutethimide. We conclude that estrogen suppression therapy with aminoglutethimide is a feasible alternative to surgical hypophysectomy in providing endocrine suppression and palliation in advanced breast carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0018648726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018648726&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197906)43:6<2207::AID-CNCR2820430608>3.0.CO;2-1

DO - 10.1002/1097-0142(197906)43:6<2207::AID-CNCR2820430608>3.0.CO;2-1

M3 - Article

VL - 43

SP - 2207

EP - 2214

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -